Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19063190 | COMPOSITIONS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND METHODS FOR MAKING AND USING THE SAME | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 18140214 | Diabetes Biomarkers | April 2023 | May 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18295226 | T CELL RECEPTOR-DEFICIENT CHIMERIC ANTIGEN RECEPTOR T-CELLS AND METHODS OF USE THEREOF | April 2023 | June 2025 | Allow | 27 | 1 | 1 | No | No |
| 18109719 | ANTIBODIES THAT BIND HUMAN C6 AND USES THEREOF | February 2023 | August 2024 | Allow | 18 | 0 | 1 | Yes | No |
| 17749362 | ANTIBODIES THAT BIND TO C1S AND USES THEREOF | May 2022 | December 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17580974 | Compositions Comprising Apoptotic Signaling and Methods for Induction of Antigen-Specific Tolerance | January 2022 | June 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17457785 | DUAL CHIMERIC ANTIGEN RECEPTOR TARGETING EPCAM AND ICAM-1 | December 2021 | April 2025 | Abandon | 40 | 2 | 1 | Yes | No |
| 17602434 | COMBINATION THERAPY WITH AN ANTI BCMA ANTIBODY AND A GAMMA SECRETASE INHIBITOR | October 2021 | July 2025 | Allow | 45 | 1 | 0 | No | No |
| 17432920 | ARTIFICIAL IMMUNOSURVEILLANCE CHIMERIC ANTIGEN RECEPTOR AND CELLS EXPRESSING THE SAME | August 2021 | April 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17429876 | Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells | August 2021 | March 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17386197 | ANTIBODIES SPECIFIC TO CD44 | July 2021 | November 2024 | Allow | 40 | 1 | 0 | No | No |
| 17424794 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) | July 2021 | June 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17421249 | ENGINEERED TUBEROUS SCLEROSIS COMPLEX 2 POLYPEPTIDES | July 2021 | May 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17291069 | Combinations for Treating Cancer | May 2021 | November 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17286206 | IDENTIFICATION AND TARGETING OF PATHOGENIC EXTRACELLULAR MATRIX FOR DIAGNOSIS AND TREATMENT OF CANCER AND OTHER DISEASES | April 2021 | December 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17272176 | IMPROVED THERAPEUTIC T CELL | February 2021 | November 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17150973 | HYDROPHOBIC INTERACTION CHROMATOGRAPHY FOR VIRAL CLEARANCE | January 2021 | October 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17259736 | METHOD FOR PRODUCING GAMMA DELTA T CELLS | January 2021 | April 2025 | Allow | 51 | 2 | 1 | No | No |
| 17132726 | IL3Ralpha Antibodies and Uses Thereof | December 2020 | August 2024 | Allow | 44 | 2 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner O'BRIEN, LEA S works in Art Unit 1646 and has examined 18 patent applications in our dataset. With an allowance rate of 44.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner O'BRIEN, LEA S's allowance rate of 44.4% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by O'BRIEN, LEA S receive 1.17 office actions before reaching final disposition. This places the examiner in the 19% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by O'BRIEN, LEA S is 44 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +49.2% benefit to allowance rate for applications examined by O'BRIEN, LEA S. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 99% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 99% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.